Literature DB >> 4320954

SV40-tumorigenesis in mouse.

T Wesslén.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1970        PMID： 4320954     DOI： 10.1111/j.1699-0463.1970.tb04331.x

Source DB:  PubMed          Journal:  Acta Pathol Microbiol Scand B Microbiol Immunol        ISSN： 0365-5571


× No keyword cloud information.
  7 in total

1.  Macrophage-resistant murine simian virus 40 tumors express a retroviral type-specific gp70.

Authors:  S K Chapes; A E O'Neill; L Flaherty; L R Gooding
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

2.  Tumorigenicity of simian virus 40-hepatocyte cell lines: effect of in vitro and in vivo passage on expression of liver-specific genes and oncogenes.

Authors:  C D Woodworth; J W Kreider; L Mengel; T Miller; Y L Meng; H C Isom
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

Review 3.  The immunopathology of SV40-induced transformation.

Authors:  P T Mora
Journal:  Springer Semin Immunopathol       Date:  1982

Review 4.  Experimental strategies for modification of histocompatibility antigens in tumor cells.

Authors:  J Vogel; K Tanaka; G S Hoekzema; G Jay
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

5.  Immunologic selection of simian virus 40 (SV40) T-antigen-negative tumor cells which arise by excision of early SV40 DNA.

Authors:  P T Mora; C L Parrott; K Baksi; V McFarland
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

6.  Tumor induction by simian virus 40 in mice is controlled by long-term persistence of the viral genome and the immune response of the host.

Authors:  J Abramczuk; S Pan; G Maul; B B Knowles
Journal:  J Virol       Date:  1984-02       Impact factor: 5.103

7.  Driving adenovirus type 12-transformed BALB/c mouse cells to express high levels of class I major histocompatibility complex proteins enhances, rather than abrogates, their tumorigenicity.

Authors:  S Soddu; A M Lewis
Journal:  J Virol       Date:  1992-05       Impact factor: 5.103
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.